In a real‑world scenario, you would replace the generic descriptors above with the exact specifications that the actual JUQ‑139 product sheet provides.
| Parameter | Method | Result | |-------------------------|-------------------------------------|--------| | Aqueous solubility (pH 7.4) | Kinetic shake‑flask (25 °C) | 12 µM | | Log D 7.4 (octanol/water) | HPLC‑based pH‑stat | 2.1 | | PAMPA permeability | Parallel artificial membrane assay | 1.8 × 10⁻⁶ cm s⁻¹ | | Microsomal stability (human) | 30 min incubation with pooled HLM, NADPH | t½ = 85 min | | CYP inhibition (IC₅₀) | Panel of CYP3A4, 2C9, 2D6 | >10 µM (no inhibition) | JUQ-139
As the quest for knowledge continues, we invite readers to contribute to the discussion, sharing their expertise and insights on the mysterious "JUQ-139." In a real‑world scenario, you would replace the
If you could provide more context or clarify what you're looking for, I'd be more than happy to assist you further! structure‑based drug design
: By providing a unique reference point for data entries, identifiers like JUQ-139 ensure that information can be easily retrieved, updated, or referenced.
Understanding the significance of JUQ-139 requires delving into the specific context in which it is used. For instance:
JUQ‑139, PI3K‑α inhibitor, heterocyclic scaffold, anticancer, structure‑based drug design, kinase selectivity